Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 20/20 | 0.65 |
| ▸ | NR1H2 | P55055 | 18/20 | 0.65 |
| ▸ | PPARD | Q03181 | 11/20 | 0.63 |
| ▸ | PPARA | Q07869 | 9/20 | 0.63 |
| ▸ | PPARG | P37231 | 7/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6347990 | 0.92 | NR1H3 (0.65) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL6343436 | 0.92 | NR1H3 (0.65) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL6346534 | 0.90 | NR1H3 (0.62) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL6355046 | 0.90 | NR1H3 (0.68) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL6346234 | 0.90 | NR1H3 (0.69) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL6343419 | 0.89 | NR1H3 (0.67) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL6346583 | 0.88 | NR1H3 (0.64) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL6799183 | 0.87 | NR1H3 (0.71) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL6349256 | 0.86 | NR1H3 (0.70) | NR1H3NR1H2PPARDPPARAPPARG | |
| SCHEMBL6349269 | 0.86 | NR1H3 (0.70) | NR1H3NR1H2PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113419-A1 | Therapeutic compounds for treating dyslipidemic conditions | HUANG SHAEI Y (US) | 2005-05-26 | — | — | US | claimed |
| US-20050113419-A1 | Therapeutic compounds for treating dyslipidemic conditions | HUANG SHAEI Y (US) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113419-A1 | Therapeutic compounds for treating dyslipidemic conditions | NR1H2, NR1H3, LDLR | NR1H3 2/4885NR1H2 1/4885PPARD 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.